Getinge to acquire Applikon Biotechnology B.V.

news-releasesApplikon Biotechnology B.V.
December 20th 2019

Delft, The Netherlands: – Getinge announces today an agreement to acquire 100% of the shares in Applikon Biotechnology B.V. from Applikon Biotechnology Holding B.V.

“Applikon Biotechnology has a strong portfolio of world class bioreactor solutions which will be a positive addition to Getinge’s existing offer towards the biopharma segment, the fastest growing area within Life Science”, says Mattias Perjos, President & CEO Getinge. “This deal further broadens our position within solutions for efficient, safe and contamination-free research and production processes.”

Applikon Biotechnology B.V. is leading in the development and supply of advanced bioreactor systems for the research and production of vaccines and antibodies in the biopharmaceutical industry, as well as enzymes and bio-plastics for industrial biotechnology. The value of the global bioreactor market is estimated to be SEK 10 B with an expected growth rate 2019-2024 of approximately 10% per year. Applikon Biotechnology B.V. is a privately-held company, founded in 1973 and has its head office in Delft, The Netherlands. The company employs approximately 180 employees worldwide and works mainly through a global distribution network.

“Through Applikon Biotechnology B.V., Getinge will be able to offer customers better solutions and knowledge covering the entire process from initial screening to full-scale production, using a fully scalable platform”, says Arthur Oudshoorn, CEO of Applikon Biotechnology B.V.. “Getinge’s global footprint will substantially strengthen our access to the market and further accelerate Applikon’s growth.”

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

About Applikon Biotechnology

Netherlands-based Applikon Biotechnology B.V. (Applikon) is a manufacturer that specializes in upstream bioprocess equipment for the life sciences industries. Its mission is to provide reliable solutions for the bioprocess market to enable improved quality of life.

Applikon’s core business is in the development and supply of advanced bioreactor systems from laboratory scale, to pilot, to production scale, partnering with customers to implement scalable platforms from initial screening through development and full-scale production for a global client base that includes pharma and biotech companies, food industry, CROs, CMOs, governmental and academic organizations.

Applikon designs, develops and assembles bioreactor systems, with all design and manufacturing conducted in-house. The Applikon portfolio covers key product and service areas including bioreactor cultivation systems, BioBundle turnkey systems, the unique BioSep Acoustic Perfusion System cell retention device, process control systems to automate bioprocesses and a range of proprietary AppliSens sensors, and automation (monitoring and data management) solutions.

Apart from its standard cultivation and turnkey systems, Applikon also offers Special Projects: custom solutions aimed at helping clients fulfill strategic needs such as long-term development, capability expansion and upscaling.

Applikon is headquartered at Delft in The Netherlands with subsidiaries in the UK, New Jersey and California, USA and a distributor network covering more than 35 countries.